US-based Protaryx Medical has completed a first-in-human trial of its transseptal puncture (TSP) device. The company’s trial enrolled five patients, with the TSP procedure carried out using its device ...
Protaryx Medical, a Maryland-based company dedicated to “minimally invasive left-heart interventional therapies,” announced that its Transseptal Puncture Device received 510(k) clearance from the FDA.
BALTIMORE--(BUSINESS WIRE)--Protaryx Medical, a pioneer in medical device innovation, is proud to announce the successful completion of its First-in-Human (FIH) study, demonstrating the transformative ...
The occurrence of acute brain lesions was lower with a transseptal puncture than with a conventional retrograde aortic approach in patients undergoing left ventricular catheter ablation, with no ...
Protaryx Medical has received the US Food and Drug Administration (FDA) 510(k) clearance to market its proprietary transseptal puncture device. The development supports Protaryx Medical’s efforts to ...
TCT 82: Single Versus Dual Antiplatelet Therapy in Transcatheter Aortic Valve Replacement A Meta-analysis of Safety and Efficacy Outcomes Receive the the latest news, research, and presentations from ...
Protaryx Medical, an innovative medical device company developing disruptive access solutions for minimally invasive left-heart procedures, today announced that it has received 510(k) clearance from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results